Department of Neurosurgery, University of Texas Health Science Center, San Antonio, Texas, USA.
Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
World Neurosurg. 2022 Oct;166:e546-e550. doi: 10.1016/j.wneu.2022.07.047. Epub 2022 Jul 19.
Mobile stroke units (MSUs) have been implemented worldwide for stroke care, but outcome data are lacking to show their efficacy specifically in patients undergoing mechanical thrombectomy (MT). Here, we include patients from our stroke network MSU and compare them to patients who arrived conventionally.
A retrospective review of a stroke database was performed to identify patients who underwent MT after arrival via an MSU from August 2019 to December 2020. Demographic factors, past medical history, stroke characteristics, treatment variables, complications, and functional outcomes were recorded. These were compared to date-matched patients who underwent MT after arrival via conventional means.
Seven patients were treated with MT after arriving by an MSU. These patients were compared to 50 date-matched patients who underwent thrombectomy after arrival through conventional means. No statistically significant difference between cohorts was observed in terms of demographic variables, comorbidities, stroke characteristics, or tissue plasminogen activator administration. Patients from the MSU cohort had significantly shorter time from symptom onset to groin puncture time (191.33 minutes ±77.53 vs. 483.51 minutes ±322.66, P = 0.034). Importantly, MSU-transferred patients had significantly better discharge functional status measured by using the modified Rankin Scale (1.86 ± 1.35 vs. 3.57 ± 1.88, P = 0.024). No significant difference in final thrombolysis in cerebral infarction score, complications, length of stay, or mortality was observed.
Our pilot study demonstrates the efficacy of the MSU in decreasing door-to-puncture time and a concordant improvement in the discharge modified Rankin Scale score. Further prospective studies are needed to assess cost-efficacy and optimal protocol for MSUs in stroke care.
移动卒中单元(MSU)已在全球范围内用于卒中治疗,但缺乏结果数据表明其在接受机械取栓(MT)的患者中的疗效。在此,我们纳入了来自我们卒中网络 MSU 的患者,并将其与常规到达的患者进行比较。
对卒中数据库进行回顾性分析,以确定 2019 年 8 月至 2020 年 12 月期间通过 MSU 到达后接受 MT 的患者。记录人口统计学因素、既往病史、卒中特征、治疗变量、并发症和功能结局。将这些与通过常规途径到达后接受 MT 的日期匹配患者进行比较。
有 7 名患者通过 MSU 到达后接受 MT 治疗。将这些患者与通过常规途径到达后接受血栓切除术的 50 名日期匹配患者进行比较。两组患者在人口统计学变量、合并症、卒中特征或组织型纤溶酶原激活剂给药方面无统计学显著差异。MSU 组患者从症状发作到腹股沟穿刺的时间明显缩短(191.33±77.53 分钟 vs. 483.51±322.66 分钟,P=0.034)。重要的是,MSU 转院患者的改良 Rankin 量表(mRS)评分出院功能状态明显更好(1.86±1.35 vs. 3.57±1.88,P=0.024)。最终的脑梗死溶栓评分、并发症、住院时间或死亡率无显著差异。
我们的初步研究表明,MSU 可缩短门到穿刺时间,并一致改善出院时的 mRS 评分。需要进一步的前瞻性研究来评估 MSU 在卒中治疗中的成本效益和最佳方案。